Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022

  • ID: 3845818
  • Report
  • Region: Global
  • 157 pages
  • Hoovers Research
1 of 3
This analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Breast Cancer Therapeutics". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:

- Market Sizing estimations and forecasts for 6 years across the given market segments
- Identifying market dynamics (Drivers, Restraints, Opportunities, Threats, Challenges and Opportunities, )
- Strategic recommendations in key business segments based on the market estimations
- Regional and country level market analysis
- Competitive landscaping of major market players
- Company profiling covering the financials, recent activities and the future strategies
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Breast Cancer Therapeutics Market by Clinical Study
5.1 Introduction
5.2 Phase I
5.3 Phase II
5.4 Phase III Drugs

6 Breast Cancer Therapeutics Market by Drug Class
6.1 Introduction
6.2 Mitotic Inhibitors
6.2.1 Ixempra (Ixabepilone)
6.2.2 Halaven (Eribulin)
6.2.3 Taxotere (Docetaxel)
6.3 Anti-metabolites
6.3.1 Gemzar (Gemcitabine)
6.4 Hormone Receptor
6.4.1 Zoladex
6.4.2 Faslodex
6.4.3 Fareston
6.5 Aromatase Inhibitors
6.5.1 Femara (Leterozole)
6.5.2 Arimidex (Anastrozole)
6.5.3 Aromasin (Exemestane)
6.5.4 Ibrance (Palbociclib)
6.5.5 Afinitor (Everolimus)
6.6 HER2 Inhibitors
6.6.1 Kadcyla (Ado-trastuzumab emtansine)
6.6.2 Tykerb (Lapatinib)
6.6.3 Perjeta (Pertuzumab)
6.6.4 Herceptin (Trastuzumab)

7 Geographical Segmentation
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.2.6 Rest of Europe
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 Rest of the World
7.4.1 Latin America
7.4.2 Middle East
7.4.3 Africa
7.4.4 Others

8 Vendor Landscaping
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiles
9.1 Bayer HealthCare
9.1.1 Business Overview
9.1.2 SWOT Analysis
9.1.3 Financial Overview
9.1.4 Strategy
9.1.5 Key Activities
9.2 Eli Lily
9.3 Pfizer
9.4 Novartis
9.5 Eisai
9.6 Halozyme Therapeutics
9.7 Roche
9.8 Puma Biotechnology
9.9 Janssen Biotech
9.10 AbbVie
9.11 BioMarin
9.12 Array BioPharma
9.13 Merck
9.14 Syndax
9.15 MacroGenics
9.16 ImmunoGen
9.17 Santen Pharma
9.18 Celgene
9.19 Oncothyreon
9.20 AstraZeneca
9.21 Sprint Bioscience
9.22 Genentech
9.23 Galena Biopharma
9.24 Lycera
9.25 CTI BioPharma
10 Appendix
11 Disclaimer

List of Tables
Table 1 Global Breast Cancer Therapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Breast Cancer Therapeutics Market Analysis, by Clinical Study, 2013-2022 ($MN)
Table 3 Global Phase I Market Analysis, by Region, 2013-2022 ($MN)
Table 4 Global Phase II Market Analysis, by Region, 2013-2022 ($MN)
Table 5 Global Phase III Drugs Market Analysis, by Region, 2013-2022 ($MN)
Table 6 Global Breast Cancer Therapeutics Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 7 Global Mitotic Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 8 Global Mitotic Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 9 Global Anti-metabolites Market Analysis, by Region, 2013-2022 ($MN)
Table 10 Global Anti-metabolites Market Analysis, by Type, 2013-2022 ($MN)
Table 11 Global Hormone Receptor Market Analysis, by Region, 2013-2022 ($MN)
Table 12 Global Hormone Receptor Market Analysis, by Type, 2013-2022 ($MN)
Table 13 Global Aromatase Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 14 Global Aromatase Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 15 Global HER2 Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 16 Global HER2 Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 17 North America Breast Cancer Therapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 18 North America Breast Cancer Therapeutics Market Analysis, by Clinical Study, 2013-2022 ($MN)
Table 19 North America Phase I Market Analysis, by Country, 2013-2022 ($MN)
Table 20 North America Phase II Market Analysis, by Country, 2013-2022 ($MN)
Table 21 North America Phase III Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 22 North America Breast Cancer Therapeutics Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 23 North America Mitotic Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 24 North America Mitotic Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 25 North America Anti-metabolites Market Analysis, by Country, 2013-2022 ($MN)
Table 26 North America Anti-metabolites Market Analysis, by Type, 2013-2022 ($MN)
Table 27 North America Hormone Receptor Market Analysis, by Country, 2013-2022 ($MN)
Table 28 North America Hormone Receptor Market Analysis, by Type, 2013-2022 ($MN)
Table 29 North America Aromatase Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 30 North America Aromatase Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 31 North America HER2 Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 32 North America HER2 Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 33 Europe Breast Cancer Therapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 34 Europe Breast Cancer Therapeutics Market Analysis, by Clinical Study, 2013-2022 ($MN)
Table 35 Europe Phase I Market Analysis, by Country, 2013-2022 ($MN)
Table 36 Europe Phase II Market Analysis, by Country, 2013-2022 ($MN)
Table 37 Europe Phase III Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 38 Europe Breast Cancer Therapeutics Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 39 Europe Mitotic Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 40 Europe Mitotic Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 41 Europe Anti-metabolites Market Analysis, by Country, 2013-2022 ($MN)
Table 42 Europe Anti-metabolites Market Analysis, by Type, 2013-2022 ($MN)
Table 43 Europe Hormone Receptor Market Analysis, by Country, 2013-2022 ($MN)
Table 44 Europe Hormone Receptor Market Analysis, by Type, 2013-2022 ($MN)
Table 45 Europe Aromatase Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 46 Europe Aromatase Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 47 Europe HER2 Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 48 Europe HER2 Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 49 Asia Pacific Breast Cancer Therapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 50 Asia Pacific Breast Cancer Therapeutics Market Analysis, by Clinical Study, 2013-2022 ($MN)
Table 51 Asia Pacific Phase I Market Analysis, by Country, 2013-2022 ($MN)
Table 52 Asia Pacific Phase II Market Analysis, by Country, 2013-2022 ($MN)
Table 53 Asia Pacific Phase III Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 54 Asia Pacific Breast Cancer Therapeutics Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 55 Asia Pacific Mitotic Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 56 Asia Pacific Mitotic Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 57 Asia Pacific Anti-metabolites Market Analysis, by Country, 2013-2022 ($MN)
Table 58 Asia Pacific Anti-metabolites Market Analysis, by Type, 2013-2022 ($MN)
Table 59 Asia Pacific Hormone Receptor Market Analysis, by Country, 2013-2022 ($MN)
Table 60 Asia Pacific Hormone Receptor Market Analysis, by Type, 2013-2022 ($MN)
Table 61 Asia Pacific Aromatase Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 62 Asia Pacific Aromatase Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 63 Asia Pacific HER2 Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 64 Asia Pacific HER2 Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 65 Rest of the World Breast Cancer Therapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 66 Rest of the World Breast Cancer Therapeutics Market Analysis, by Clinical Study, 2013-2022 ($MN)
Table 67 Rest of the World Phase I Market Analysis, by Country, 2013-2022 ($MN)
Table 68 Rest of the World Phase II Market Analysis, by Country, 2013-2022 ($MN)
Table 69 Rest of the World Phase III Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 70 Rest of the World Breast Cancer Therapeutics Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 71 Rest of the World Mitotic Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 72 Rest of the World Mitotic Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 73 Rest of the World Anti-metabolites Market Analysis, by Country, 2013-2022 ($MN)
Table 74 Rest of the World Anti-metabolites Market Analysis, by Type, 2013-2022 ($MN)
Table 75 Rest of the World Hormone Receptor Market Analysis, by Country, 2013-2022 ($MN)
Table 76 Rest of the World Hormone Receptor Market Analysis, by Type, 2013-2022 ($MN)
Table 77 Rest of the World Aromatase Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 78 Rest of the World Aromatase Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Table 79 Rest of the World HER2 Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 80 Rest of the World HER2 Inhibitors Market Analysis, by Type, 2013-2022 ($MN)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll